Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer

被引:85
作者
Gheiler, EL
Tefilli, MV
Tiguert, R
Grignon, D
Cher, ML
Sakr, W
Pontes, JE
Wood, DP
机构
[1] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Urol, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA
关键词
D O I
10.1016/S0090-4295(98)00096-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To determine preradiation and preoperative clinical staging and postoperative pathologic factors that can predict disease-free survival in patients undergoing salvage surgery for radio-recurrent prostate cancer. Methods. A retrospective review was performed on 40 patients who underwent salvage surgery for radio-recurrent prostate cancer. Preradiation and preoperative clinical staging factors, as well as pathologic stage were analyzed as predictors of disease-free survival. Biochemical failure was defined as a persistent serum prostate-specific antigen (PSA) elevation greater than 0.4 ng/mL. Results. As a group, salvage surgery provided excellent clinical disease control in 35 of 40 patients (87.5%). Overall, 18 of 38 (47.4%) patients analyzed had no evidence of biochemical progression. Preradiation clinical stage and pathologically organ-confined disease were statistically significant predictors of disease-free survival (P = 0.03 and P = 0.02, respectively). Seminal vesicle invasion and positive lymph nodes were the worst pathologic prognostic factors. Preoperative clinical Tie disease approached statistical significance in predicting pathologically organ-confined disease and disease-free survival (P = 0.08 and P = 0.07, respectively). Conclusions. Ideal candidates for salvage surgery should have preradiation and preoperative clinically organ-confined disease. All patients with pathologically organ-confined disease following salvage prostatectomy were disease free at a mean follow-up of 36.1 months. Salvage surgery, although technically feasible, should not be widely advocated as an effective curative treatment in patients with locally advanced disease at the time of diagnosis. (C) 1998, Elsevier Science Inc. All rights reserved.
引用
收藏
页码:789 / 795
页数:7
相关论文
共 23 条
  • [1] SALVAGE SURGERY PLUS ANDROGEN DEPRIVATION FOR RADIORESISTANT PROSTATIC ADENOCARCINOMA
    AHLERING, TE
    LIESKOVSKY, G
    SKINNER, DG
    [J]. JOURNAL OF UROLOGY, 1992, 147 (03) : 900 - 902
  • [2] SHORT-TERM OUTCOMES AFTER CRYOSURGICAL ABLATION OF THE PROSTATE IN MEN WITH RECURRENT PROSTATE CARCINOMA FOLLOWING RADIATION-THERAPY
    BALES, GT
    WILLIAMS, MJ
    SINNER, M
    THISTED, RA
    CHODAK, GW
    [J]. UROLOGY, 1995, 46 (05) : 676 - 680
  • [3] Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level
    Forman, JD
    Meetze, K
    Pontes, E
    Wood, DP
    Shamsa, F
    Rana, T
    Porter, AT
    [J]. JOURNAL OF UROLOGY, 1997, 158 (04) : 1436 - 1439
  • [4] EFFECT OF LOCAL TUMOR-CONTROL ON DISTANT METASTASIS AND SURVIVAL IN PROSTATIC ADENOCARCINOMA
    KUBAN, DA
    ELMAHDI, AM
    SCHELLHAMMER, PF
    [J]. UROLOGY, 1987, 30 (05) : 420 - 426
  • [5] Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease-free survival
    Lee, WR
    Hanlon, AL
    Hanks, GE
    [J]. JOURNAL OF UROLOGY, 1996, 156 (02) : 450 - 453
  • [6] CRITICAL-EVALUATION OF SALVAGE SURGERY FOR RADIO-RECURRENT RESISTANT PROSTATE-CANCER
    LERNER, SE
    BLUTE, ML
    ZINCKE, H
    [J]. JOURNAL OF UROLOGY, 1995, 154 (03) : 1103 - 1109
  • [7] RADICAL PROSTATECTOMY AFTER DEFINITIVE RADIATION-THERAPY FOR PROSTATE-CANCER
    LINK, P
    FREIHA, FS
    [J]. UROLOGY, 1991, 37 (03) : 189 - 192
  • [8] USE OF PERCUTANEOUS TRANSPERINEAL AU-198 SEEDS TO TREAT RECURRENT PROSTATE ADENOCARCINOMA AFTER FAILURE OF DEFINITIVE RADIOTHERAPY
    LOENING, SA
    TURNER, JW
    [J]. PROSTATE, 1993, 23 (04) : 283 - 290
  • [9] MILLER EB, 1993, UROLOGY, V41, P311
  • [10] OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V269, P57